020 7713 0990
10 July 2017


The combined treatment drugs market for haemophilia A and B across seven major countries will be almost $8 billion US by 2026 – a rise from $6.7 billion US today, according to data and insight specialists GlobalData.

Its report, PharmaPoint: Haemophilia A and B – Global Drug Forecast and Market Analysis to 2026, reveals that the increased market in US, France, Germany, Italy, Spain, the UK and Japan includes increasing rates of routine prophylaxis in paediatric and adult haemophilia A and B, and the introduction and uptake of new long-acting factors and alternative coagulation promoters (ACPs).

Dr Chiara Marchetti, GlobalData healthcare analyst, said the transition from short-acting recombinant factor VIII (rFVIII) treatment to long-acting rFVIII products, launched in 2014, for people with haemophilia A has been slower than anticipated.

'This is primarily because the limited half-life extension obtained from FVIII does not translate to meaningful reduction in dosing frequency in the haemophilia A prophylactic setting, unlike what has been achieved by long-acting recombinant FIX (clotting factor IX) for haemophilia B,' she said.

'Indeed, the long-term prospects for the long-acting rFVIII drug class through 2026 appear bleak, as sales are anticipated to be lost to ACPs that will enter the haemophilia A market in 2019.'

GlobalData believes that ACP set to launch include Roche’s emicizumab in the inhibitor and non-inhibitor haemophilia A market segments, and Alnylam/Genzyme’s fitusiran in the inhibitor and non-inhibitor haemophilia A and B market segments.

The molecular structure and subcutaneous administration will enable fewer doses, which will improve convenience.

Dr Marchetti added: 'Because the costs associated with haemophilia care are constantly escalating, pricing strategy will be the key to the success of these new agents.

'Despite the advantages provided by the drug, GlobalData expects Roche to seek a limited premium over long-acting rFVIII.

'Given the high level of unmet need in the inhibitor segment and the good uptake expected among haemophilia A patients, emicizumab will be able to exploit cross-segment efficacy to become a blockbuster in the haemophilia space, with peak-year sales of $2.6 billion in 2026.'

Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.